Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 2/20 | 0.31 |
| ▸ | ELOC | Q15369 | 2/20 | 0.31 |
| ▸ | ELOB | Q15370 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | MAP1B | P46821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26412265 | 0.99 | TTR (0.42) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL20016562 | 0.94 | TTR (0.45) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL26286101 | 0.92 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL29351004 | 0.92 | TTR (0.46) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL25052808 | 0.92 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL25204552 | 0.90 | TTR (0.46) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL22452311 | 0.88 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL24176337 | 0.88 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL26284929 | 0.88 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL12342504 | 0.87 | TTR (0.44) | TTRIL2KLKB1FOLH1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | TTR 1898/4885IL2 3867/4885KLKB1 1027/4885 |
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | EPHA5, EPHA3, EPHA1 | TTR 2100/4885IL2 3633/4885KLKB1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.